

Drug Pricing Legislation: Senate

Bill Title	Sponsors/ Cosponsors	Brief Description	Legislative Status
<i>Reducing Drug Prices for Seniors Act (S. 2617)</i> Introduced: July 31, 2025 Legislative Text	Sen. Jacky Rosen (D-NV) 1 Cosponsor (1 R, 0 D)	To amend title XVIII of the Social Security Act to require that coinsurance for drugs under Medicare part D be based on the drug's net price and not the drug's list price.	Senate - 07/31/2025 Read twice and referred to the Committee on Finance.
<i>Repealing the Trump Sick Tax Act (S. 2447)</i> Introduced: July 24, 2025 Legislative Text	Sen. Peter Welch (D-VT) 4 Cosponsors (4 D, 0 R)	To repeal changes to Medicaid cost sharing requirements and the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program.	Senate - 07/24/2025 Read twice and referred to the Committee on Finance.
<i>Short on Competition Act (S. 2345)</i> Introduced: July 17, 2025 Legislative Text	Sen. Amy Klobuchar (D-MN) 3 Cosponsors (2 R, 1 D)	To allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages.	Senate - 07/17/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>Optimizing Research Progress Hope And New (ORPHAN) Cures Act (S. 1862)</i> Introduced: May 22, 2025 Legislative Text	Sen. John Barrasso (R-WY) 1 Cosponsor (1 D, 0 R)	To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.	Latest Action - Similar Provision Included in the OBBBA (P.L. 119-21 ; Sec. 71203).

<p><i>Strengthening Medicare And Reducing Taxpayer (SMART) Prices Act (S. 1836)</i></p> <p>Introduced: May 21, 2025</p> <p>Legislative Text</p>	<p>Sen. Amy Klobuchar (D-MN)</p> <p>26 Cosponsors (25 D, 1 I, 0 R)</p>	<p>To amend title XVIII of the Social Security Act to strengthen the drug pricing reforms in the Inflation Reduction Act.</p>	<p>Senate - 05/21/2025 Read twice and referred to the Committee on Finance.</p>
<p><i>Prescription Drug Price Relief Act of 2025 (S. 1818)</i></p> <p>Introduced: May 20, 2025</p> <p>Legislative Text</p>	<p>Sen. Bernie Sanders (I-VT)</p> <p>7 Cosponsors (7 D, 0 R)</p>	<p>To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.</p>	<p>Senate - 05/20/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</p>
<p><i>End Price Gouging for Medications Act (S. 1753)</i></p> <p>Introduced: May 14, 2025</p> <p>Legislative Text</p>	<p>Sen. Jeff Merkley (D-OR)</p> <p>3 Cosponsors (2 D, 1 I, 0 R)</p>	<p>To require the Secretary of Health and Human Services to establish reference prices for prescription drugs for purposes of Federal health programs.</p>	<p>Senate - 05/14/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</p>
<p><i>Medicaid VBPs for Patients (MVP) Act (S. 1637)</i></p> <p>Introduced: May 7, 2025</p> <p>Legislative Text</p>	<p>Sen. Markwayne Mullin (R-OK)</p> <p>2 Cosponsors (1 R, 1 D)</p>	<p>To amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting under such arrangements.</p>	<p>Senate - 05/07/2025 Read twice and referred to the Committee on Finance.</p>
<p><i>Fair Prescription Drug Prices for Americans Act (S. 1587)</i></p> <p>Introduced: May 5, 2025</p> <p>Legislative Text</p>	<p>Sen. Josh Hawley (R-MO)</p> <p>1 Cosponsor (1 D, 0 R)</p>	<p>To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations.</p>	<p>Senate - 05/05/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</p>
<p><i>Lower Drug Costs for Families Act (S. 1186)</i></p> <p>Introduced: March 27, 2025</p> <p>Legislative Text</p>	<p>Sen. Catherine Cortez Masto (D-NV)</p> <p>12 Cosponsors (11 D, 1 I, 0 R)</p>	<p>To amend title XVIII of the Social Security Act to apply prescription drug inflation rebates to drugs furnished in the commercial market and to change the base year for rebate calculations.</p>	<p>Senate - 03/27/2025 Read twice and referred to the Committee on Finance.</p>

<p><i>Ensuring Pathways to Innovative Cures (EPIC) Act of 2025 (S. 832)</i></p> <p>Introduced: March 4, 2025</p> <p>Legislative Text</p>	<p>Sen. Thom Tillis (R-NC)</p> <p>7 Cosponsors (7 R, 0 D)</p>	<p>To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - the so-called “pill penalty” bill.</p>	<p>Senate - 03/04/2025 Read twice and referred to the Committee on Finance.</p>
<p><i>Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (S. 694)</i></p> <p>Introduced: February 24, 2025</p> <p>Legislative Text</p>	<p>Sen. Thom Tillis (R-NC)</p> <p>3 Cosponsors (2 D, 1 R)</p>	<p>To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.</p>	<p>Senate - 02/24/2025 Read twice and referred to the Committee on Finance.</p>
<p><i>Safe and Affordable Drugs from Canada Act of 2025 (S. 641)</i></p> <p>Introduced: February 19, 2025</p> <p>Legislative Text</p>	<p>Sen. Amy Klobuchar (D-MN)</p> <p>7 Cosponsors (5 D, 1 R, 1 I)</p>	<p>To amend the Federal Food, Drug, and Cosmetic Act to allow for the personal importation of safe and affordable drugs from approved pharmacies in Canada.</p>	<p>Senate - 02/19/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</p>
<p><i>Capping Prescription Costs Act of 2025 (S. 529)</i></p> <p>Introduced: February 11, 2025</p> <p>Legislative Text</p>	<p>Sen. Raphael Warnock (D-GA)</p> <p>13 Cosponsors (13 D, 0 R)</p>	<p>To limit cost-sharing for prescription drugs, aiming to set annual out-of-pocket prescription drug cost limits at \$2,000 for individuals and \$4,000 for families with private insurance.</p>	<p>Senate - 02/11/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</p>
<p>Drug Pricing Legislation: House</p>			
<p><i>Use Sovereignty To reduce Rx (USTRx) Act (H.R. 4780)</i></p> <p>Introduced: July 29, 2025</p> <p>Legislative Text</p>	<p>Rep. Jodey Arrington (R-TX)</p> <p>5 Cosponsors (5 R, 0 D)</p>	<p>To identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based policies and unfairly exploit United States innovation.</p>	<p>House - 07/29/2025 Referred to the Committee on Ways and Means.</p>

<p><i>340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support (340B PATIENTS) Act of 2025 (H.R. 4581)</i></p> <p>Introduced: July 22, 2025</p> <p>Legislative Text</p>	<p>Rep. Doris Matsui (D-CA)</p> <p>11 Cosponsors (11 D, 0 R)</p>	<p>To ensure the accessibility of drugs furnished through the drug discount program under section 340B of the Public Health Service Act.</p>	<p>House - 07/22/2025 Referred to the Committee on Energy and Commerce.</p>
<p><i>Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299)</i></p> <p>Introduced: July 7, 2025</p> <p>Legislative Text</p>	<p>Rep. Greg Murphy (R-NC)</p> <p>3 Cosponsors (2 R, 1 D)</p>	<p>To amend title XVIII of the Social Security Act to provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation.</p>	<p>House - 07/07/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Cutting Copays Act (H.R. 4139)</i></p> <p>Introduced: June 25, 2025</p> <p>Legislative Text</p>	<p>Rep. Morgan McGarvey (D-KY)</p> <p>1 Cosponsor (1 R, 0 D)</p>	<p>To eliminate cost-sharing for generic drugs for those with the lowest-income under the Medicare prescription drug benefit's Low-Income Subsidy Program beginning in 2026.</p>	<p>House - 06/25/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Prescription Drug Price Relief Act of 2025 (H.R. 3546)</i></p> <p>Introduced: May 21, 2025</p> <p>Legislative Text</p>	<p>Rep. Ro Khanna (D-CA)</p> <p>4 Cosponsors (4 D, 0 R)</p>	<p>To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.</p>	<p>House - 05/21/2025 Referred to the Committees on Energy and Commerce and Judiciary.</p>
<p><i>Global Fairness in Drug Pricing Act (H.R. 3493)</i></p> <p>Introduced: May 19, 2025</p> <p>Legislative Text</p>	<p>Rep. Ro Khanna (D-CA)</p> <p>4 Cosponsors (3 R, 1 D)</p>	<p>To reduce prescription drug prices by aligning U.S. prices with international benchmarks.</p>	<p>House - 05/19/2025 Referred to the Committees on Energy and Commerce, Ways and Means, and Judiciary.</p>

<p><i>End Price Gouging for Medications Act</i> (H.R. 3391)</p> <p>Introduced: May 14, 2025</p> <p>Legislative Text</p>	<p>Rep. Debbie Dingell (D-MI)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To require the Secretary of Health and Human Services to establish reference prices for prescription drugs for purposes of Federal health programs.</p>	<p>House - 05/14/2025 Referred to the Committees on Energy and Commerce, Ways and Means, Oversight, et al.</p>
<p><i>Fair Prescription Drug Prices for Americans Act</i> (H.R. 3375)</p> <p>Introduced: May 13, 2025</p> <p>Legislative Text</p>	<p>Rep. Jefferson Van Drew (R-NJ)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations.</p>	<p>House - 05/13/2025 Referred to the Committee on Energy and Commerce.</p>
<p><i>Affordable and Safe Prescription Drug Importation Act of 2025</i> (H.R. 3162)</p> <p>Introduced: May 1, 2025</p> <p>Legislative Text</p>	<p>Rep. Jan Schakowsky (D-IL)</p> <p>5 Cosponsors (5 D, 0 R)</p>	<p>To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.</p>	<p>House - 05/01/2025 Referred to the Committee on Energy and Commerce.</p>
<p><i>Old Drugs, New Cures Act</i> (H.R. 2542)</p> <p>Introduced: April 1, 2025</p> <p>Legislative Text</p>	<p>Rep. Don Davis (D-NC)</p> <p>1 Cosponsor (1 R, 0 D)</p>	<p>To amend titles XVIII and XIX of the Social Security Act to provide that priority research drugs shall not be treated as line extensions of existing drugs for purposes of calculating manufacturer rebates under the Medicare and Medicaid programs.</p>	<p>House - 04/01/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Lower Drug Costs for Families Act</i> (H.R. 2554)</p> <p>Introduced: April 1, 2025</p> <p>Legislative Text</p>	<p>Rep. Steven Horsford (D-NV)</p> <p>2 Cosponsors (2 D, 0 R)</p>	<p>To amend title XVIII of the Social Security Act to apply prescription drug inflation rebates to drugs furnished in the commercial market and to change the base year for rebate calculations.</p>	<p>House - 04/01/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>

<p><i>Capping Prescription Costs Act of 2025</i> (H.R. 2553)</p> <p>Introduced: April 1, 2025</p> <p>Legislative Text</p>	<p>Rep. Steven Horsford (D-NV)</p> <p>8 Cosponsors (8 D, 0 R)</p>	<p>To limit cost-sharing for prescription drugs, aiming to set annual out-of-pocket prescription drug cost limits at \$2,000 for individuals and \$4,000 for families with private insurance.</p>	<p>House - 04/01/2025 Referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce.</p>
<p><i>Ensuring Access to Essential Drugs Act</i> (H.R. 1922)</p> <p>Introduced: March 6, 2025</p> <p>Legislative Text</p>	<p>Rep. Andrew Garbarino (R-NY)</p> <p>2 Cosponsors (1 R, 1 D)</p>	<p>To amend title XVIII of the Social Security Act to exempt certain drugs from the part D manufacturer discount program under the Medicare program.</p>	<p>House - 03/06/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Maintaining Investments in New Innovation (MINI) Act</i> (H.R. 1672)</p> <p>Introduced: February 27, 2025</p> <p>Legislative Text</p>	<p>Rep. Don Davis (D-NC)</p> <p>20 Cosponsors (17 R, 3 D)</p>	<p>To amend title XI of the Social Security Act to protect access to genetically targeted technologies.</p>	<p>House - 02/27/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Reciprocity Ensures Streamlined Use of Lifesaving Treatments (RESULT) Act of 2025</i> (H.R. 1632)</p> <p>Introduced: February 26, 2025</p> <p>Legislative Text</p>	<p>Rep. Chip Roy (R-TX)</p> <p>1 Cosponsor (1 R, 0 D)</p>	<p>To amend the Federal Food, Drug, and Cosmetic Act to provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad.</p>	<p>House - 02/26/2025 Referred to the Committees on Energy and Commerce and Rules.</p>
<p><i>Ensuring Pathways to Innovative Cures (EPIC) Act</i> (H.R. 1492)</p> <p>Introduced: February 21, 2025</p> <p>Legislative Text</p>	<p>Rep. Greg Murphy (R-NC)</p> <p>60 Cosponsors (59 R, 1 D)</p>	<p>To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - the so-called “pill penalty” bill.</p>	<p>House - 02/21/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act</i> (H.R. 1476)</p> <p>Introduced: February 21, 2025</p> <p>Legislative Text</p>	<p>Rep. Richard Hudson (R-NC)</p> <p>5 Cosponsors (3 R, 2 D)</p>	<p>To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.</p>	<p>House - 02/21/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>

<p><i>Reducing Drug Prices for Seniors Act</i> (H.R. 1244)</p> <p>Introduced: February 12, 2025</p> <p>Legislative Text</p>	<p>Rep. Don Davis (D-NC)</p> <p>1 Cosponsors (1 R, 0 D)</p>	<p>To amend title XVIII of the Social Security Act to require that coinsurance for drugs under Medicare part D be based on the drug's actual acquisition cost and not the drug's wholesale acquisition cost.</p>	<p>House - 02/12/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Optimizing Research Progress Hope And New (ORPHAN) Cures Act</i> (H.R. 946)</p> <p>Introduced: February 4, 2025</p> <p>Legislative Text</p>	<p>Rep. John Joyce (R-PA)</p> <p>17 Cosponsors (9 D, 8 R)</p>	<p>To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.</p>	<p>Latest Action - Similar Provision Included in the OBBBA (P.L. 119-21; Sec. 71203).</p>
<p><i>Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act</i> (H.R. 267)</p> <p>Introduced: January 9, 2025</p> <p>Legislative Text</p>	<p>Rep. Warren Davidson (R-OH)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To provide statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services.</p>	<p>House - 01/09/2025 Referred to the Committee on Energy and Commerce.</p>
<p><i>Rural 340B Access Act of 2025</i> (H.R. 44)</p> <p>Introduced: January 3, 2025</p> <p>Legislative Text</p>	<p>Rep. Jack Bergman (R-MI)</p> <p>3 Cosponsors (3 D, 0 R)</p>	<p>To make rural emergency hospitals (REHs) eligible to purchase drugs from manufacturers at discounted prices by participating in the Health Resources and Services Administration's (HRSA) 340B drug pricing program.</p>	<p>House - 01/03/2025 Referred to the Committee on Energy and Commerce.</p>

Pharmacy Benefit Manager (PBM) Legislation: Senate

Bill Title	Sponsors/ Cosponsors	Brief Description	Legislative Status
<i>Patients Deserve Price Tags Act (S. 2355)</i> Introduced: July 17, 2025 Legislative Text	Sen. Roger Marshall (R-KS) 5 Cosponsors (3 R, 2 D)	To amend the Public Health Service Act to provide for hospital and insurer price transparency.	Senate - 07/17/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>Protecting Pharmacies in Medicaid Act (S. 927)</i> Introduced: March 11, 2025 Legislative Text	Sen. Peter Welch (D-VT) 3 Cosponsors (2 R, 1 D)	To amend title XIX of the Social Security Act to ensure accurate payments to pharmacies under Medicaid and to prevent the use of abusive spread pricing practices under Medicaid.	Senate - 03/11/2025 Read twice and referred to the Committee on Finance.
<i>Patients Before Middlemen (PBM) Act (S. 882)</i> Introduced: March 6, 2025 Legislative Text	Sen. Marsha Blackburn (R-TN) 7 Cosponsors (4 D, 3 R)	To amend title XVIII of the Social Security Act to assure pharmacy access and choice for beneficiaries under prescription drug plans and MA-PD plans and to establish requirements of pharmacy benefit managers under Medicare part D.	Senate - 03/06/2025 Read twice and referred to the Committee on Finance.
<i>Help Ensure Lower Patient (HELP) Copays Act (S. 864)</i> Introduced: March 5, 2025 Legislative Text	Sen. Roger Marshall (R-KS) 11 Cosponsors (6 D, 5 R)	To amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans - also known as the "Part D delinking bill."	Senate - 03/05/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>Pharmacy Benefit Manager Transparency Act of 2025 (S. 526)</i> Introduced: February 11, 2025 Legislative Text	Sen. Chuck Grassley (R-IA) 12 Cosponsors (8 R, 4 D)	To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs.	Senate - 02/11/2025 Read twice and referred to the Committee on Commerce, Science, and Transportation.

<p><i>Prescription Pricing for the People Act of 2025</i> (S. 527)</p> <p>Introduced: February 11, 2025</p> <p>Legislative Text</p>	<p>Sen. Chuck Grassley (R-IA)</p> <p>13 Cosponsors (7 R, 6 D)</p>	<p>To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations.</p>	<p>Senate - 04/10/2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.</p> <p>Senate Judiciary Committee - 04/03/2025 Ordered to be reported without amendment favorably.</p>
Pharmacy Benefit Manager (PBM) Legislation: House			
<p><i>Fair Pharmacies for Federal Employees Act of 2025</i> (H.R. 4409)</p> <p>Introduced: July 15, 2025</p> <p>Legislative Text</p>	<p>Rep. Raja Krishnamoorthi (D-IL)</p> <p>2 Cosponsors (1 D, 1 R)</p>	<p>To prohibit the common ownership pharmacy benefit managers and pharmacies that provide services under contracts with Federal health plans for Federal employees.</p>	<p>House - 07/15/2025 Referred to the Committee on Oversight and Government Reform.</p>
<p><i>Pharmacy Benefit Manager (PBM) Reform Act of 2025</i> (H.R. 4317)</p> <p>Introduced: July 10, 2025</p> <p>Legislative Text</p>	<p>Rep. Buddy Carter (R-GA)</p> <p>24 Cosponsors (12 R, 12 D)</p>	<p>To assure pharmacy access and choice for Medicare beneficiaries.</p>	<p>House - 07/10/2025 Referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce.</p>
<p><i>Prescription Drug Transparency and Affordability Act</i> (H.R. 2450)</p> <p>Introduced: March 27, 2025</p> <p>Legislative Text</p>	<p>Rep. Kristen McDonald Rivet (D-MI)</p> <p>3 Cosponsors (2 R, 1 D)</p>	<p>To amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1984 to increase oversight of pharmacy benefit management services.</p>	<p>House - 03/27/2025 Referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce.</p>
<p><i>Delinking Revenue from Unfair Gouging (DRUG) Act</i> (H.R. 2214)</p> <p>Introduced: March 18, 2025</p> <p>Legislative Text</p>	<p>Rep. Mariannette Miller-Meeks (R-IA)</p> <p>5 Cosponsors (3 D, 2 R)</p>	<p>To improve services provided by pharmacy benefit managers.</p>	<p>House - 03/18/2025 Referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce.</p>

<p><i>Saving Seniors Money on Prescriptions Act</i> (H.R. 950)</p> <p>Introduced: February 4, 2025</p> <p>Legislative Text</p>	<p>Rep. Greg Landsman (D-OH)</p> <p>1 Cosponsor (1 R, 0 D)</p>	<p>To establish reporting requirements for pharmacy benefit managers under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.</p>	<p>House - 02/04/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Medicaid Third Party Liability Act</i> (H.R. 497)</p> <p>Introduced: January 16, 2025</p> <p>Legislative Text</p>	<p>Rep. Dan Crenshaw (R-TX)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To modify requirements relating to Medicaid third-party liability.</p>	<p>House - 01/16/2025 Referred to the Committee on Energy and Commerce.</p>

Direct-to-Consumer (DTC) Drug Advertising Legislation: Senate

Bill Title	Sponsors/ Cosponsors	Brief Description	Legislative Status
<i>End Prescription Drug Ads Now Act (S. 2068)</i> Introduced: June 12, 2025 Legislative Text	Sen. Bernie Sanders (I-VT) 6 Cosponsors (5 D, 1 I, 0 R)	To ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.	Senate - 06/12/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>No Handouts for Drug Advertisements Act (S. 1785)</i> Introduced: May 15, 2025 Legislative Text	Sen. Josh Hawley (R-MO) 1 Cosponsor (1 D, 0 R)	To amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for certain drugs.	Senate - 05/15/2025 Read twice and referred to the Committee on Finance.
<i>Protecting Patients from Deceptive Drug Ads Act (S. 652)</i> Introduced: February 20, 2025 Legislative Text	Sen. Dick Durbin (D-IL) 1 Cosponsor (1 R, 0 D)	To provide for the regulation of certain communications regarding prescription drugs.	Senate - 02/20/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>Responsibility in Drug Advertising Act of 2025 (S. 483)</i> Introduced: February 6, 2025 Legislative Text	Sen. Angus King (I-ME) 2 Cosponsors (2 D, 0 R)	To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.	Senate - 02/06/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>Drug-price Transparency for Consumers (DTC) Act of 2025 (S. 229)</i> Introduced: January 23, 2025 Legislative Text	Sen. Dick Durbin (D-IL) 9 Cosponsors (4 R, 4 D, 1 I)	To amend title XI of the Social Security Act to require that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information.	Senate - 01/23/2025 Read twice and referred to the Committee on Finance.

Direct-to-Consumer (DTC) Drug Advertising Legislation: House

<p><i>End Prescription Drug Ads Now Act (H.R. 4605)</i></p> <p>Introduced: July 22, 2025</p> <p>Legislative Text</p>	<p>Rep. Jerry Nadler (D-NY)</p> <p>2 Cosponsors (2 D, 0 R)</p>	<p>To ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.</p>	<p>House - 07/22/2025 Referred to the Committee on Energy and Commerce.</p>
<p><i>Plain Prescription Prices Act (H.R. 4623)</i></p> <p>Introduced: July 22, 2025</p> <p>Legislative Text</p>	<p>Rep. Nikema Williams (D-GA)</p> <p>3 Cosponsors (2 R, 1 D)</p>	<p>To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.</p>	<p>House - 07/22/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>Drug-price Transparency for Consumers (DTC) Act of 2025 (H.R. 3789)</i></p> <p>Introduced: June 5, 2025</p> <p>Legislative Text</p>	<p>Rep. David Taylor (R-OH)</p> <p>3 Cosponsors (2 D, 1 R)</p>	<p>To amend title XI of the Social Security Act to require that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information.</p>	<p>House - 06/05/2025 Referred to the Committees on Energy and Commerce and Ways and Means.</p>
<p><i>No Handouts for Drug Advertisements Act (H.R. 3010)</i></p> <p>Introduced: April 24, 2025</p> <p>Legislative Text</p>	<p>Rep. Greg Murphy (R-NC)</p> <p>3 Cosponsors (2 D, 1 R)</p>	<p>To amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for certain drugs.</p>	<p>House - 04/24/2025 Referred to the Committee on Ways and Means.</p>
<p><i>Responsibility in Drug Advertising Act of 2025 (H.R. 1117)</i></p> <p>Introduced: February 7, 2025</p> <p>Legislative Text</p>	<p>Rep. Rosa L. DeLauro (D-CT)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.</p>	<p>House - 02/07/2025 Referred to the Committee on Energy and Commerce.</p>

Patent Exclusivity Legislation: Senate

Bill Title	Sponsors/ Cosponsors	Brief Description	Legislative Status
<p><i>Medication Affordability and Patent Integrity Act (S. 2658)</i></p> <p>Introduced: August 1, 2025</p> <p>Legislative Text</p>	<p>Sen. Maggie Hassan (D-NH)</p> <p>1 Cosponsor (1 R, 0 D)</p>	<p>To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office.</p>	<p>Senate - 08/01/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</p>
<p><i>Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act (S. 2620)</i></p> <p>Introduced: July 31, 2025</p> <p>Legislative Text</p>	<p>Sen. Dick Durbin (D-IL)</p> <p>1 Cosponsor (1 R, 0 D)</p>	<p>To amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications.</p>	<p>Senate - 07/31/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</p>
<p><i>Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276)</i></p> <p>Introduced: July 15, 2025</p> <p>Legislative Text</p>	<p>Sen. Peter Welch (D-VT)</p> <p>2 Cosponsors (1 R, 1 D)</p>	<p>To address patent thickets.</p>	<p>Senate - 07/15/2025 Read twice and referred to the Committee on the Judiciary.</p>
<p><i>Interagency Patent Coordination and Improvement Act of 2025 (S. 1097)</i></p> <p>Introduced: March 24, 2025</p> <p>Legislative Text</p>	<p>Sen. Dick Durbin (D-IL)</p> <p>4 Cosponsors (2 R, 2 D)</p>	<p>To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents.</p>	<p>Senate - 04/10/2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.</p> <p>Senate Judiciary Committee - 04/03/2025 Ordered to be reported with amendments favorably.</p>

Patent Exclusivity Legislation: House

<p><i>Eliminating Thickets to Increase Competition (ETHIC) Act (H.R. 3269)</i></p> <p>Introduced: May 8, 2025</p> <p>Legislative Text</p>	<p>Rep. Jodey Arrington (R-TX)</p> <p>6 Cosponsors (4 D, 2 R)</p>	<p>To address patent thickets.</p>	<p>House - 05/08/2025 Referred to the Committee on the Judiciary.</p>
<p><i>Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act (H.R. 1051)</i></p> <p>Introduced: February 6, 2025</p> <p>Legislative Text</p>	<p>Rep. Nikki Budzinski (D-IL)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period.</p>	<p>House - 02/06/2025 Referred to the Committee on Energy and Commerce.</p>
<p><i>Prompt Approval of Safe Generic Drugs Act (H.R. 843)</i></p> <p>Introduced: January 31, 2025</p> <p>Legislative Text</p>	<p>Rep. Nanette D. Barragán (D-CA)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To authorize the Food and Drug Administration to approve certain applications to market a generic drug despite the omission of certain safety information from the generic drug's labeling.</p>	<p>House - 01/31/2025 Referred to the Committee on Energy and Commerce.</p>
<p><i>Stopping Pharma's Ripoffs and Drug Savings For All Act (H.R. 890)</i></p> <p>Introduced: January 31, 2025</p> <p>Legislative Text</p>	<p>Rep. Pat Ryan (D-NY)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To amend title 35, United States Code, to prevent double patenting.</p>	<p>House - 01/31/2025 Referred to the Committee on the Judiciary.</p>

Biosimilars Legislation: Senate

Bill Title	Sponsors/ Cosponsors	Brief Description	Legislative Status
<i>Biosimilar Red Tape Elimination Act (S. 1954)</i> Introduced: June 4, 2025 Legislative Text	Sen. Mike Lee (R-UT) 4 Cosponsors (2 R, 2 D)	To improve the requirements for making a determination of interchangeability of a biological product and its reference product.	Senate - 06/04/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>Producing Incentives for Long-term production of Lifesaving Supply of medicine (PILLS) Act (S. 1891)</i> Introduced: May 22, 2025 Legislative Text	Sen. Tom Cotton (R-AR) 0 Cosponsors (0 R, 0 D)	To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit.	Senate - 05/22/2025 Read twice and referred to the Committee on Finance.
<i>Expedited Access to Biosimilars Act (S. 1414)</i> Introduced: April 10, 2025 Legislative Text	Sen. Rand Paul (R-KY) 1 Cosponsor (1 R, 0 D)	To amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.	Senate - 04/10/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>Increasing Transparency in Generic Drug Applications Act (S. 1302)</i> Introduced: April 3, 2025 Legislative Text	Sen. Maggie Hassan (D-NH) 4 Cosponsors (3 R, 1 D)	To provide for increased transparency in generic drug applications.	Senate - 04/03/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
<i>Preserve Access to Affordable Generics and Biosimilars Act (S. 1096)</i> Introduced: March 24, 2025 Legislative Text	Sen. Amy Klobuchar (D-MN) 8 Cosponsors (5 D, 3 R)	To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.	Senate - 04/10/2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 46. Senate Judiciary Committee - 04/03/2025 Ordered to be reported with an amendment in the nature of a substitute favorably.

<p><i>Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act (S. 1095)</i></p> <p>Introduced: March 24, 2025</p> <p>Legislative Text</p>	<p>Sen. Amy Klobuchar (D-MN)</p> <p>6 Cosponsors (4 D, 2 R)</p>	<p>To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns.</p>	<p>Senate - 04/10/2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.</p> <p>Senate Judiciary Committee - 04/03/2025 Ordered to be reported without amendment favorably.</p>
<p><i>Affordable Prescriptions for Patients Act (S. 1041)</i></p> <p>Introduced: March 13, 2025</p> <p>Legislative Text</p>	<p>Sen. John Cornyn (R-TX)</p> <p>3 Cosponsors (2 D, 1 R)</p>	<p>To amend title 35, United States Code, to address the infringement of patents that claim biological products.</p>	<p>Senate - 04/10/2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.</p> <p>Senate Judiciary Committee - 04/03/2025 Ordered to be reported with amendments favorably.</p>
<p><i>Drug Competition Enhancement Act (S. 1040)</i></p> <p>Introduced: March 13, 2025</p> <p>Legislative Text</p>	<p>Sen. John Cornyn (R-TX)</p> <p>3 Cosponsors (2 D, 1 R)</p>	<p>To amend the Federal Trade Commission Act to prohibit product hopping.</p>	<p>Senate - 04/10/2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.</p> <p>Senate Judiciary Committee - 04/03/2025 Ordered to be reported with an amendment favorably.</p>
<p><i>Skinny Labels, Big Savings Act (S. 43)</i></p> <p>Introduced: January 9, 2025</p> <p>Legislative Text</p>	<p>Sen. John Hickenlooper (D-CO)</p> <p>3 Cosponsors (2 R, 1 D)</p>	<p>To provide a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs.</p>	<p>Senate - 01/09/2025 Read twice and referred to the Committee on the Judiciary.</p>
<p>Biosimilars Legislation: House</p>			
<p><i>Increasing Transparency in Generic Drug Applications Act (H.R. 1843)</i></p> <p>Introduced: March 5, 2025</p>	<p>Rep. Neal Dunn (R-FL)</p> <p>1 Cosponsor (1 D, 0 R)</p>	<p>To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.</p>	<p>House - 03/05/2025 Referred to the Committee on Energy and Commerce.</p>

Legislative Text			
<p><i>Producing Incentives for Long-term production of Lifesaving Supply of medicine (PILLS) Act (H.R. 1396)</i></p> <p>Introduced: February 14, 2025</p> <p>Legislative Text</p>	<p>Rep. Claudia Tenney (R-NY)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit.</p>	<p>House - 02/14/2025 Referred to the Committee on Ways and Means.</p>
<p><i>To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines. (H.R. 1142)</i></p> <p>Introduced: February 7, 2025</p> <p>Legislative Text</p>	<p>Rep. David Schweikert (R-AZ)</p> <p>0 Cosponsors (0 R, 0 D)</p>	<p>To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines.</p>	<p>House - 02/07/2025 Referred to the Committee on Energy and Commerce.</p>